PharmaEssentia Corporation, a biopharmaceutical company located in Burlington, Massachusetts, has recently seen their Biologics License Application (BLA) approved by the FDA. This application was submitted for ropeginterferon alfa-2b, a treatment…
According to a story from The Intercept, Gilead Sciences' drug remdesivir is being touted in the media as a major development in the treatment of COVID-19, the illness caused by…
In a story from Multiple Sclerosis News Today, multiple sclerosis is known for its variability- one patient's experience may look nothing like a friend's with the same disease. For this…
According to a recent article in Medscape, the FDA has issued accelerated approval for Bristol-Myers Squibb's Pomalyst (pomalidomide). Pomalyst was approved as the first new oral treatment for AIDS-related…
As reported in GSK, the FDA has just granted priority review to Nucala (mepolizumab), a targeted biological treatment to help patients with hypereosinophilic syndrome (HES). If the medication is accepted,…
Ultomiris, a product of Alexion Pharmaceuticals, has recently been studied in a Phase 3 clinical trial. This study was intended to ultomiris' effect on life-threatening complications of atypical hemolytic uremic…
A team of researchers from the Perelman School of Medicine and several other institutions recently reported a significant reduction in tumor growth in myeloid immune cells using an experimental…
According to a story from globenewswire.com, the biopharmaceutical company Apellis Pharmaceuticals, Inc. has announced that it is currently making plans to submit a New Drug Application (NDA) to the US…
According to a story from UNC Health Care, the Belgian drug company Argenx recently announced that its investigational treatment efgartigimod has performed well in a phase 3 clinical trial. The…
A team of researchers from the Perelman School of Medicine and several other institutions recently reported a significant reduction in tumor growth in myeloid immune cells using an experimental…
According to a story from globenewswire.com, the biopharmaceutical company Orphazyme A/S has recently announced that it has submitted its New Drug Application (NDA) for its experimental treatment arimoclomol to the…
According to a story from Parkinson's News Today, an analysis of results from several different clinical trials suggests that the drug istradefylline (marketed as Nourianz) can reduce the duration of…
The European Commission has recently granted approval to Bristol Myers Squibb (BMS) for their multiple sclerosis (MS) treatment, Zeposia. It has already been approved by the FDA in the US…
Libtayo, a product of Regeneron Pharmaceuticals, has shown positive results in the treatment of those with advanced cutaneous squamous cell carcinoma. This data comes from a Phase 2 trial and…
In 2015 families in Wales and England were given the good news that tolvaptan (JINARC®), which was developed for autosomal dominant polycystic kidney disease (ADPKD), will be available within one…
.jpg)
Neurotrope is launching a long term Phase 2 trial of Bryostatin-1, which is a treatment for Alzheimer's disease. The National Institutes of Health (NIH) will be joining this study, giving…
According to a story from Parkinson's News Today, the Vercise system, developed by Boston Scientific as a method of deep brain stimulation, was able to provide benefit to Parkinson's disease…
CytRx Corporation has recently received the Fast Track designation for their ALS treatment, arimoclomol. This status was also given for the treatment of Niemann-Pick disease and sporadic Inclusion Body Myositis…
According to a story from Parkinson's News Today, ropinirole (marketed as Requip) skin patches proved capable of improving motor function in patients with advanced Parkinson's disease when compared to placebo.…
The virtually-held National Kidney Foundation 2020 Spring Clinical Meetings explored various topics relating to nephrological conditions, treatment, and patient outcomes. One presentation, spearheaded by Dr. Adam Weinstein, MD, and…
In an article in Medical Xpress, Japanese doctors have performed a “first” by transplanting liver cells (made with embryonic stem cells) into a newborn. The six-day-old infant was diagnosed with…
As reported in Guru Focus, biotech company Protagonist Therapeutics has announced progression in their Phase 2 study on PTG-300 as treatment for patients with polycythemia vera, a rare cancer. Dr.…
According to a story from prnewswire.com, the Chiesi Global Rare Diseases and the biopharmaceutical company ProTalix Biotherapeutics have recently announced that they have submitted a Biologics License Application (BLA) for…
Passage Bio has been granted the Rare Pediatric Disease designation for their GM1 gangliosidosis treatment, PBGM01. This designation means that Passage will receive a priority review voucher, and it is…
The medical realm is changing - but how does that impact patient care and clinical expectations? The National Hemophilia Foundation discusses how clinical expectations for patients with hemophilia don't necessarily…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
